Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 59

1.

Disrupting the CD95-PLCγ1 interaction prevents Th17-driven inflammation.

Poissonnier A, Guégan JP, Nguyen HT, Best D, Levoin N, Kozlov G, Gehring K, Pineau R, Jouan F, Morere L, Martin S, Thomas M, Lazaro E, Douchet I, Ducret T, van de Weghe P, Blanco P, Jean M, Vacher P, Legembre P.

Nat Chem Biol. 2018 Dec;14(12):1079-1089. doi: 10.1038/s41589-018-0162-9. Epub 2018 Nov 14.

PMID:
30429604
2.

Inhibition of IRE1 RNase activity modulates the tumor cell secretome and enhances response to chemotherapy.

Logue SE, McGrath EP, Cleary P, Greene S, Mnich K, Almanza A, Chevet E, Dwyer RM, Oommen A, Legembre P, Godey F, Madden EC, Leuzzi B, Obacz J, Zeng Q, Patterson JB, Jäger R, Gorman AM, Samali A.

Nat Commun. 2018 Aug 15;9(1):3267. doi: 10.1038/s41467-018-05763-8.

3.

Tumor analysis: freeze-thawing cycle of triple-negative breast cancer cells alters tumor CD24/CD44 profiles and the percentage of tumor-infiltrating immune cells.

Le Gallo M, de la Motte Rouge T, Poissonnier A, Lavoué V, Tas P, Leveque J, Godey F, Legembre P.

BMC Res Notes. 2018 Jun 20;11(1):401. doi: 10.1186/s13104-018-3504-5.

4.

Nonapoptotic functions of Fas/CD95 in the immune response.

Guégan JP, Legembre P.

FEBS J. 2018 Mar;285(5):809-827. doi: 10.1111/febs.14292. Epub 2017 Nov 16. Review.

5.

CD95/Fas, Non-Apoptotic Signaling Pathways, and Kinases.

Le Gallo M, Poissonnier A, Blanco P, Legembre P.

Front Immunol. 2017 Sep 27;8:1216. doi: 10.3389/fimmu.2017.01216. eCollection 2017. Review.

6.

Erratum.

Legembre P.

Methods Mol Biol. 2017;1557:E1. doi: 10.1007/978-1-4939-6780-3_22. No abstract available.

PMID:
28247335
7.

Myeloid-derived suppressor cell, arginase-1, IL-17 and cl-CD95L: an explosive cocktail in lupus?

Flynn RJ, Legembre P.

Ann Transl Med. 2016 Dec;4(24):554. doi: 10.21037/atm.2016.12.35. No abstract available.

8.

Boyden Chamber Assay to Study of Cell Migration Induced by Metalloprotease Cleaved-CD95L.

Poissonnier A, Legembre P.

Methods Mol Biol. 2017;1557:117-123. doi: 10.1007/978-1-4939-6780-3_12.

PMID:
28078588
9.

Study of the CD95-Mediated Non-apoptotic Signaling Pathway: PI3K.

Fouqué A, Legembre P.

Methods Mol Biol. 2017;1557:103-110. doi: 10.1007/978-1-4939-6780-3_10.

PMID:
28078586
10.

Proximity Ligation Assay (PLA) to Evaluate DISC and MISC Composition.

Thomas M, Legembre P.

Methods Mol Biol. 2017;1557:41-48. doi: 10.1007/978-1-4939-6780-3_5.

PMID:
28078581
11.

CD95 Stimulation with CD95L and DISC Analysis.

Le Gallo M, Legembre P.

Methods Mol Biol. 2017;1557:11-18. doi: 10.1007/978-1-4939-6780-3_2.

PMID:
28078578
12.

TRAIL receptor gene editing unveils TRAIL-R1 as a master player of apoptosis induced by TRAIL and ER stress.

Dufour F, Rattier T, Constantinescu AA, Zischler L, Morlé A, Ben Mabrouk H, Humblin E, Jacquemin G, Szegezdi E, Delacote F, Marrakchi N, Guichard G, Pellat-Deceunynck C, Vacher P, Legembre P, Garrido C, Micheau O.

Oncotarget. 2017 Feb 7;8(6):9974-9985. doi: 10.18632/oncotarget.14285.

13.

CD95-Mediated Calcium Signaling Promotes T Helper 17 Trafficking to Inflamed Organs in Lupus-Prone Mice.

Poissonnier A, Sanséau D, Le Gallo M, Malleter M, Levoin N, Viel R, Morere L, Penna A, Blanco P, Dupuy A, Poizeau F, Fautrel A, Seneschal J, Jouan F, Ritz J, Forcade E, Rioux N, Contin-Bordes C, Ducret T, Vacher AM, Barrow PA, Flynn RJ, Vacher P, Legembre P.

Immunity. 2016 Jul 19;45(1):209-23. doi: 10.1016/j.immuni.2016.06.028.

14.

The apoptotic members CD95, BclxL, and Bcl-2 cooperate to promote cell migration by inducing Ca(2+) flux from the endoplasmic reticulum to mitochondria.

Fouqué A, Lepvrier E, Debure L, Gouriou Y, Malleter M, Delcroix V, Ovize M, Ducret T, Li C, Hammadi M, Vacher P, Legembre P.

Cell Death Differ. 2016 Oct;23(10):1702-16. doi: 10.1038/cdd.2016.61. Epub 2016 Jul 1.

15.

The cleaved FAS ligand activates the Na(+)/H(+) exchanger NHE1 through Akt/ROCK1 to stimulate cell motility.

Monet M, Poët M, Tauzin S, Fouqué A, Cophignon A, Lagadic-Gossmann D, Vacher P, Legembre P, Counillon L.

Sci Rep. 2016 Jun 15;6:28008. doi: 10.1038/srep28008.

16.

Review of PI3K/mTOR Inhibitors Entering Clinical Trials to Treat Triple Negative Breast Cancers.

Fouqué A, Jean M, Weghe Pv, Legembre P.

Recent Pat Anticancer Drug Discov. 2016;11(3):283-96. Review.

PMID:
27194555
17.

Chemotherapy with ceramide in TNBC.

Legembre P, Micheau O, Ségui B.

Oncoscience. 2015 Aug 21;2(10):817-8. eCollection 2015. No abstract available.

18.

A Novel Covalent mTOR Inhibitor, DHM25, Shows in Vivo Antitumor Activity against Triple-Negative Breast Cancer Cells.

Fouqué A, Delalande O, Jean M, Castellano R, Josselin E, Malleter M, Shoji KF, Hung MD, Rampanarivo H, Collette Y, van de Weghe P, Legembre P.

J Med Chem. 2015 Aug 27;58(16):6559-73. doi: 10.1021/acs.jmedchem.5b00991. Epub 2015 Aug 14.

PMID:
26237138
19.

Sphingolipids modulate the epithelial-mesenchymal transition in cancer.

Levade T, Andrieu-Abadie N, Micheau O, Legembre P, Ségui B.

Cell Death Discov. 2015 Oct 12;1:15001. doi: 10.1038/cddiscovery.2015.1. eCollection 2015. No abstract available.

20.

The CD95/CD95L signaling pathway: a role in carcinogenesis.

Fouqué A, Debure L, Legembre P.

Biochim Biophys Acta. 2014 Aug;1846(1):130-41. doi: 10.1016/j.bbcan.2014.04.007. Epub 2014 Apr 26. Review.

Supplemental Content

Loading ...
Support Center